Prof. Michael A. Linden
Department of Lab Medicine and Pathology
University of Minnesota Medical Center, USA
Email: linde013@umn.edu
Qualifications
2010-2011 University of Washington Medical Center, WAHematopathology fellowship, USA
2006-2010 Combined Anatomic and Clinical Pathology residency training
1998-2006 M.N., M.D., Ph.D., (Medical Scientist Training Program)
1994-1998 M.N., B.A., in Biology (Summa Cum Laude), University of Minnesota, Minneapolis, Saint Mary’s University, USA
1990-1994 Memorial High School, Eau Claire, WI, Summa Cum Laude
Publications(Selected)
-
Linden MA, Gopal A, and Edlefsen KL. Acute appendicitis in a man undergoing therapy for mantle cell lymphoma. Case Reports in Hematology (in press)
-
Yan D, Wang P, Linden M, Knudsen B, and Randolph T. Automated quantification of immunohistochemical staining for improved tissue microarray image scoring by Tissue Array Co-Occurrence Matrix Analysis (TACOMA). Annals of Applied Statistics (in press)
-
Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of an activated N-ras gene results in B- and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Experimental Hematology (in press)
-
Linden MA and Apple FS. Use of B-type natriuretic peptide testing in a community teaching hospital 4 years after implementation and agreement of results with discharge diagnoses. Clinical Chemistry. 2006 Apr; 52(4):767-8.
-
Dunn T, Linden MA, Vercellotti GM, and Gruessner RWG. Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clinical Transplantation. 2006 Jan; 20(1):132-5.
-
Linden MA, Kirchhof N, Kvitrud M, and Van Ness BG. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in bcl-XL transgenic mice. Leukemia Research. 2005 Apr; 29(4):435-444.
-
Cheung WC, Kim JS, Linden MA, Van Ness BG, Polakiewicz R, Janz S. Novel targeted deregulation of c-myc and bcl-XL causes plasma cell neoplasms in mice. J Clinical Investigation. 2004 Jun; 113(12):1763-73.
-
Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 2004 Apr 1; 103(7):2779-86.
-
Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and co-culture with bone marrow stromal cells. Blood. 2003 Oct 1; 102(7): 2581-92.
-
Liu X, Linden M, Van Ness B. Induced kappa receptor editing shows no allelic preference in a mouse pre-B cell line. J Immunol. 2000 Dec 15; 165(12): 7058-63.
-
Linden MA, Ward J and Cherian S. The Hematopoietic System. In: Comparative Anatomy and Histology for the Translational Pathologist: A Mouse and Human Atlas, Dintzis S and Treuting P., ed. Elsevier Press, Maryland Heights, MO, 2011.
-
MA Linden. Implementation of the PCA3 urine test: an additional tool to aid in prostate cancer diagnostic decisions. Academy of Clinical Laboratory Physicians and Scientists Annual Meeting, Nashville, TN, June 2010. Oral presentation.
-
MA Linden. Kanadaptin, a recently discovered protein with transport functionality, is overexpressed in prostate carcinoma. Canary Foundation Early Detection Symposium, Palo Alto, CA, May 2009. Poster presentation.
-
MA Linden. The histological phenotype of TMPRSS2-ERG gene fusion prostate cancer is unaltered by neoadjuvant treatment with the 5-alpha-reductase inhibitor dutasteride. American Society of Clinical Pathology, Baltimore, MD, October 2008. Poster presentation.
-
MA Linden. The prognostic power of biomarker MTA-1 for recurrence/biochemical failure post-radical prostatectomy. Canary Foundation Early Detection Symposium, Palo Alto, CA, May 2008. Poster presentation.
-
MA Linden. Targeted overexpression of mutant activated N-ras leads to aberrant plasma cell biology. American Society of Hematology, San Diego, CA, December 2004. Poster presentation.
-
MA Linden. Novel targeted deregulation of bcl-XL and c-myc leads to accelerated plasma cell malignancies. American Society of Hematology, San Diego, CA, December 2003. Oral presentation.
-
MA Linden. Targeted overexpression of bcl-XL: toward a genetically-induced model of multiple myeloma. Fund to Cure Myeloma Roundtable, New York, NY, October 2003. Oral presentation.
-
MA Linden. Novel targeted deregulation of bcl-XL and c-myc leads to accelerated plasma cell malignancies. 18th Annual National MD/PhD Student Conference, Snowmass, CO, July 2003. Oral presentation.
-
MA Linden. Novel targeted deregulation of bcl-XL and c-myc leads to accelerated plasma cell malignancies. International Workshop on Multiple Myeloma, Salamanca, Spain, May 2003. Poster presentation.
-
MA Linden. Pronounced plasma cell disease in a bcl-XL transgenic mouse. American Society of Hematology, Philadelphia, PA, December 2002. Oral presentation.
-
MA Linden. Gene profiling of IL-6 response and N-ras activating mutations in a myeloma cell line. American Society of Hematology, Orlando, FL, December 2001. Poster presentation.